ESCRS - Supplement: Keys to success with today’s presbyopia and toric lens technologies
Supplements

Supplement: Keys to success with today’s presbyopia and toric lens technologies

Supplement: Keys to success with today’s presbyopia and toric lens technologies

Conducted for the sixth time at the 39th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), the 2020 ESCRS Clinical Trends Survey comprised 145 questions and received responses from nearly 400 doctors. In terms of trends in the use of intraocular lenses (IOLs) in routine practice, survey responses suggested that implantation of presbyopia-correcting IOLs during cataract surgery has remained stable over the past five years. However, in the same period, the use of toric IOLs during cataract procedures has doubled from 7% to 14% (Figure 1). Interestingly, survey respondents reported that if ‘cost were not an issue’, 38% of patients with clinically significant astigmatism would receive a toric IOL. In regions where reimbursement is available for toric IOLs, such as Australia, the reported use of these lenses is much greater (60–70%).

Tags: presbyopia and toric lens
Latest Articles
Committing to a More Equitable Ophthalmology

Charity Committee enhances ESCRS’s reputation as a socially responsible society.

Read more...

Virtual Community Unites Ukrainian Eye Specialists

Microlearning platform proves vital to saving eyes and lives in areas of conflict.

Read more...

ESCRS Survey Shifts Industry Dial

Annual survey reveals trends and issues regarding the digital OR.

Read more...

Always Measure the Epithelium!

Epithelium thickness mapping key to better refractive outcomes.

Read more...

Brave New World of AI

More applications for anterior segment anticipated.

Read more...

Advancing Vision Research

National Eye Institute initiatives encourage AI-based innovations and data interoperability.

Read more...

Best Candidates for Phakic EDOF IOLs?

Patient profile suggests limits for phakic EDOF approach.

Read more...

Knowing Iris Repair: Iris Repair with Prosthetic Devices

New devices on the market expand available options when iris tissue is insufficient.

Read more...

Targeting the Kallikrein-Kinin System to Treat DME

Novel oral plasma kallikrein inhibitor shows promise in early clinical trial.

Read more...

Faricimab VOYAGER Study

Real-world experience with faricimab for treatment-naïve nAMD and DME is underway.

Read more...